Job Recruitment Website - Zhaopincom - Who is the chairman of Shanghai Fosun?

Who is the chairman of Shanghai Fosun?

Wu Yifang is the chairman of Fosun.

Mr. Wu Yifang, born in April 1969, is currently the executive director and chairman of Shanghai Fosun Pharma (Group) Co., Ltd., and serves as the director of several holding subsidiaries of the Company. Wu Yifang was appointed as the executive director of Fosun Pharma in August 20 16, and was appointed as the chairman of Fosun Pharma in June 2020. Wu Yifang obtained the Certificate of International Trade from Nanjing University of Science and Technology (1996) in June 2005, and obtained the Master's degree of Advanced Business Administration (Pharmaceutical Marketing) from St. Joseph University in September 2005.

Wu Yifang joined Fosun Pharma Group in April 2004, and served as Senior Vice President, Chief Operating Officer, President and CEO of Fosun Pharma. Wu Yifang is currently listed on the Hong Kong Stock Exchange (Sisram Medical; ; Stock code: 0 1696) Fu Honghanlin (stock code: 02696), a company listed on the Hong Kong Stock Exchange, is a non-executive director and a non-executive director.

Wu Yifang was awarded the May 1st Labor Medal in 20021Shanghai, the Best CEO in China in 20021Forbes, and an outstanding figure in transnational operation of China enterprises in 20 19. He also won the honorary title of Top Ten Outstanding Entrepreneurs in Xuzhou.

Brief introduction of Fosun Group

Shanghai Fosun Pharma (Group) Co., Ltd. (referred to as "Fosun Pharma"), stock code: 600 196. Shanghai, 02 196. HK), founded in 1994, is a global pharmaceutical and health industry group rooted in China and driven by innovation. Its direct business includes drugs, medical devices, medical diagnosis and medical treatment.

Fosun Pharma is patient-centered and clinical demand-oriented. Through independent research and development, cooperative development, licensing introduction and deep incubation, it continuously enriches the innovative product pipeline, enhances the research and development capabilities of FIC (first-class) and BIC (first-class) new drugs, and accelerates the research and development and transformation of innovative technologies and products.

Reference: Baidu Encyclopedia-Shanghai Fosun Pharma (Group) Co., Ltd.